ReWalk Robotics Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lifeward Ltd. Lifeward Ltd., formerly ReWalk Robotics Ltd. ReWalk Robotics Ltd., designs, develops, and commercializes wearable robotic exoskeletons and related medical technologies that enable mobility, rehabilitation, and wellness for individuals with lower limb disabilities due to spinal cord injuries, stroke, or other neurological conditions; its core products include the ReWalk Personal Exoskeleton and ReWalk 7 Personal Exoskeleton for home and community use to facilitate standing, walking, turning, and stair navigation; the ReWalk Rehabilitation Exoskeleton and ReStore soft exo-suit for clinical gait training and stroke recovery; the MyoCycle functional electrical stimulation (FES) bike for therapeutic cycling in clinics or at home; the ReBoot personal soft exo-suit for post-stroke use; and AlterG Anti-Gravity treadmill systems with pressurized air chambers to reduce body weight impact during rehabilitation, mobility training, and athletic performance. The company, founded in 2001 by Dr. Amit Goffer and headquartered at 3 Hatnufa Street, Floor 6, Yokneam Illit, Israel, with key operations in Marlborough, Massachusetts, USA, and Berlin, Germany, markets its solutions directly to healthcare institutions, rehabilitation centers, and individuals, as well as through third-party distributors and partnerships with payers like Medicare and workers' compensation providers, serving customers across the United States, Europe, Asia-Pacific, and over 20 countries worldwide. In recent developments, Lifeward completed the acquisition of AlterG Inc. in August 2023 for approximately $19 million to expand its rehabilitation portfolio with anti-gravity systems and enhance commercial scale; finalized its corporate rebranding from ReWalk Robotics Ltd. to Lifeward Ltd. in September 2024, with shares trading under the ticker LFWD effective September 13, 2024; secured FDA clearance and launched the ReWalk 7 Personal Exoskeleton in the U.S. in April 2025, installing over 20 units with positive feedback; transitioned ReWalk production in-house in Q2 2025 to cut costs and improve quality control after ending the Sanmina partnership; achieved record placements of ReWalk systems for Medicare beneficiaries since the April 2024 fee schedule and grew its U.S. ReWalk pipeline to over 130 qualified leads; formed a partnership with CorLife (a NuMotion division) to accelerate workers' compensation claims processing; and appointed Mark Grant as President and CEO and Almog Adar as CFO in 2025 to drive strategic growth and efficiency.
VA STAND Act introduced in the United States Senate
4 Must-Buy Efficient Stocks to Increase Your Portfolio Returns
Lifeward Announces Reverse Share Split
ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be considered
ReWalk Robotics (LFWD) Reports Q4 Loss, Misses Revenue Estimates
Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results
Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024
ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward
7 ‘AgeTech' Stocks to Profit From the Booming Longevity Market
ReWalk Robotics Expands Direct Sales Coverage to Canada
ReWalk Robotics Ltd. to Present at Sidoti Virtual Investor Conference on January 17
First ReWalk Personal Exoskeleton Claim Paid by Medicare
ReWalk Robotics Presents on Personal Exoskeleton Pricing at Medicare Public Meeting
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
ReWalk Robotics Demonstrates AI Autonomous Decision Making in Next Generation Exoskeleton Prototype
7 Cheap Stocks to Buy Now if You Have $100 to Spend: November Edition
ReWalk Robotics Ltd. (RWLK) Q3 2023 Earnings Call Transcript
ReWalk Robotics Reports Third Quarter 2023 Financial Results
New Bill Facilitates Veteran Access to Powered Exoskeletons